SLC26A3 and hepatocellular carcinoma: HCC vs. CLD RASSF1A, BVES and HOXA9 methylation: 73.5%/91.1%, 0.834RASSF1A, BVES and HOXA9 methylation + AFP: 83.7%/78.9%, 0.852